SOAT1 and gastric cancer: Therapy for OSCC and GC is changing, and pre-clinical studies suggest that JAK-STAT signaling could play a role in regulating the activity of Immune Checkpoint Inhibitor (ICI) therapies (71, 152, 153, 295).